GW Pharmaceuticals is a British biopharmaceutical company known for its treatment in multiple sclerosis. They are also known as one of the pioneers in the cannabis industry.
Since they were founded in 1998, they’ve been trading loudly on the Nasdaq exchange. Today, they are up more than 15% as they prepare to unveil the results from their Phase 3 Clinical trial for Epidiolex, the treatment for Lennox-Gastaut syndrome (LGS).
Epidiolex is not the only drug that is undergoing clinical trials out of GW. They have a long roster of products undergoing testing phases that will change the face of the company forever.
But perhaps what they are known for the most is the fact that they commercialized the world’s first plant-based cannabinoid prescription drug known as Sativex. This cannabis drug was finally approved for the treatment of multiple sclerosis in 27 countries.
It also helps treat spasticity, which is a condition where muscles are on an endless loop of contractions caused by stiffness or tightness of muscles. This can get in the way of regular movement, speech and gait.
Cannabis used to be viewed as a negative taboo, not to be taken seriously from a medical standpoint but that has thus changed. GW Pharmaceuticals took part in changing these points of view when it found positive results in their Phase 3 Clinical trial for the treatment of patients with Dravet’s syndrome.
When these findings were announced to the public, GW stocks went over the roof and have continued to do so up until today. They are still soaring well below their average Wall Street price target. They are expected to present favorable and positive data on their Epidiolex Clinical trials next month.
We can only hope that this will continue to change the general public’s views on cannabis and recognize its positive medical results.
